Kaitlyn Kennard1,2,3, Olivia Wang4, Stephanie Kjelstrom5, Sharon Larson5, Lina M Sizer6, Catherine Carruthers6, William B Carter6, Robin Ciocca4, Jennifer Sabol4, Thomas G Frazier6, Ned Z Carp4. 1. The Bryn Mawr Hospital, Bryn Mawr, PA, USA. Kaitlyn.kennard@gmail.com. 2. Lankenau Medical Center, Wynnewood, PA, USA. Kaitlyn.kennard@gmail.com. 3. Center for Population Health at Lankenau Institute for Medical Research, Wynnewood, PA, USA. Kaitlyn.kennard@gmail.com. 4. Lankenau Medical Center, Wynnewood, PA, USA. 5. Center for Population Health at Lankenau Institute for Medical Research, Wynnewood, PA, USA. 6. The Bryn Mawr Hospital, Bryn Mawr, PA, USA.
Abstract
BACKGROUND: Abbreviated magnetic resonance imaging (Ab-MRI) has been evaluated for elevated breast cancer risk or dense breasts but has not been evaluated across all risk profiles. METHODS: Patients selected underwent Ab-MRI from February 2020 to September 2021. Women were older than aged 30 years, up to date with screening mammography, and paid $299 cash. RESULTS: A total of 93 patients were identified with a mean age of 52 years; 92.5% were Caucasian, 0% black, and 97.9% were from high socioeconomic status. Mean Gail score was 14.2, and 83.3% had a lifetime risk of breast cancer <20%. Reasons for Ab-MRI: dense breasts (36.6%); family history (24.7%); palpable mass (12.9%). Providers ordering: OBGYN (49.5%); breast surgeon (39.1%); primary care (6.6%). Thirteen biopsies (14%) detected one breast cancer. 31.1% had a change in follow-up screening: 58.6% 6-month MRI, 20.7% 6-month mammogram, and 10.3% 6-month ultrasound. Negative predictive value was 100% (95% confidence interval [CI]: 95-100%, p < 0.0001). Sensitivity was 100% (95% CI: 2.5-100%, p < 0.0001), and specificity was 87% (95% CI: 78.3-93.1%, p < 0.0001) compared with 77.6% and 98.8% for mammography. Only one cancer was detected: cost of $27,807 plus cost of 13 MRI or ultrasound (US)-guided biopsies and additional follow-up imaging. Historically 20% of abnormalities detected on full MRI are malignant; however, 7.7% of ab-MRI abnormalities were malignant CONCLUSIONS: One third of women were recommended a change in follow-up, which predominantly included a 6-month MRI. Ab-MRI may introduce average risk women to unnecessary follow-up and increased biopsies with a lower cancer detection rate. Ab-MRI should be evaluated closely before implementation.
BACKGROUND: Abbreviated magnetic resonance imaging (Ab-MRI) has been evaluated for elevated breast cancer risk or dense breasts but has not been evaluated across all risk profiles. METHODS: Patients selected underwent Ab-MRI from February 2020 to September 2021. Women were older than aged 30 years, up to date with screening mammography, and paid $299 cash. RESULTS: A total of 93 patients were identified with a mean age of 52 years; 92.5% were Caucasian, 0% black, and 97.9% were from high socioeconomic status. Mean Gail score was 14.2, and 83.3% had a lifetime risk of breast cancer <20%. Reasons for Ab-MRI: dense breasts (36.6%); family history (24.7%); palpable mass (12.9%). Providers ordering: OBGYN (49.5%); breast surgeon (39.1%); primary care (6.6%). Thirteen biopsies (14%) detected one breast cancer. 31.1% had a change in follow-up screening: 58.6% 6-month MRI, 20.7% 6-month mammogram, and 10.3% 6-month ultrasound. Negative predictive value was 100% (95% confidence interval [CI]: 95-100%, p < 0.0001). Sensitivity was 100% (95% CI: 2.5-100%, p < 0.0001), and specificity was 87% (95% CI: 78.3-93.1%, p < 0.0001) compared with 77.6% and 98.8% for mammography. Only one cancer was detected: cost of $27,807 plus cost of 13 MRI or ultrasound (US)-guided biopsies and additional follow-up imaging. Historically 20% of abnormalities detected on full MRI are malignant; however, 7.7% of ab-MRI abnormalities were malignant CONCLUSIONS: One third of women were recommended a change in follow-up, which predominantly included a 6-month MRI. Ab-MRI may introduce average risk women to unnecessary follow-up and increased biopsies with a lower cancer detection rate. Ab-MRI should be evaluated closely before implementation.
Authors: Christiane K Kuhl; Simone Schrading; Kevin Strobel; Hans H Schild; Ralf-Dieter Hilgers; Heribert B Bieling Journal: J Clin Oncol Date: 2014-06-23 Impact factor: 44.544
Authors: Bo Hwa Choi; Nami Choi; Mi Young Kim; Jung-Hyun Yang; Young Bum Yoo; Hae Kyoung Jung Journal: Breast Cancer Res Treat Date: 2018-01 Impact factor: 4.872
Authors: D Leithner; G J Wengert; T H Helbich; S Thakur; R E Ochoa-Albiztegui; E A Morris; K Pinker Journal: Clin Radiol Date: 2017-12-09 Impact factor: 2.350
Authors: Christopher E Comstock; Constantine Gatsonis; Gillian M Newstead; Bradley S Snyder; Ilana F Gareen; Jennifer T Bergin; Habib Rahbar; Janice S Sung; Christina Jacobs; Jennifer A Harvey; Mary H Nicholson; Robert C Ward; Jacqueline Holt; Andrew Prather; Kathy D Miller; Mitchell D Schnall; Christiane K Kuhl Journal: JAMA Date: 2020-02-25 Impact factor: 157.335